Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD. Recent clinical trials have validated the efficacy of non-steroidal roflumilast 0.3% foam for the treatment of SD. In this review, we analyze the safety and efficacy profile of roflumilast 0.3% foam.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Roflumilast for the Treatment of Seborrheic Dermatitis: A Review.
Skin Therapy Lett
March 2025
University of Central Florida/HCA Healthcare Consortium, Tallahassee, FL, USA.
Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder most commonly affecting areas rich in sebaceous glands, such as the scalp, face, axilla, and groin. Several factors can precipitate SD development, such as colonization of Malassezia, sebocyte activity, impaired immunity, and environmental influences. Topical antifungals, corticosteroids, and calcineurin inhibitors are the current mainstay treatment of SD.
View Article and Find Full Text PDFPotential Applications of Chitosan in Seborrheic Dermatitis and Other Skin Diseases: A Comprehensive Review.
Clin Cosmet Investig Dermatol
March 2025
Beijing Uproven Medical Technology Co., LTD., Beijing, People's Republic of China.
This review article explores the potential applications of chitosan, a natural polysaccharide derived from crustacean shells, in the treatment of seborrheic dermatitis (SD) and other skin diseases. SD is a common chronic inflammatory skin condition characterized by erythema, scaling, itching, and an oily appearance, predominantly affecting areas rich in sebaceous glands. Current treatments, including antifungal agents, corticosteroids, and calcineurin inhibitors, offer symptomatic relief but have limitations in long-term use due to side effects and resistance issues.
View Article and Find Full Text PDFPatient and healthcare provider perspectives on treatment patterns and patient satisfaction of seborrheic dermatitis in the United States.
J Dermatolog Treat
December 2025
Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA.
Introduction: Seborrheic dermatitis (SD) affects a large, diverse population and is associated with significant morbidity/burden.
Methods: The Harris Poll conducted online surveys to understand the perceptions, preferences, and experiences regarding treatments of US patients with SD and dermatology healthcare providers (HCPs) from December 2021 to January 2022.
Results: In this survey, patients using SD treatment invested on average 34 min/d treating SD with 5.
Recognizing Dupilumab-Associated Head and Neck Dermatitis in Skin of Color: A Case Series.
Clin Case Rep
March 2025
Department of Dermatology School of Medicine, Virginia Commonwealth University Richmond Virginia USA.
Dupilumab-associated head and neck dermatitis (HND) is a rare and often underrecognized condition, especially in patients with skin of color. It can vary from subtle to severe presentations, with violaceous hues and seborrheic distribution after dupilumab initiation. Early recognition and management are crucial to prevent treatment discontinuation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!